HRT was measured in 50 CHF patients (38 male) with sinus rhythm. Patients with dilated cardiomyopathy (DCM) or previous myocardial infarction (MI) were screened by their echocardiographic data. The enrollment criterion was Circ J 2002; 66: 902 -907 (Received March 11, 2002; revised manuscript received June 14, 2002; accepted July 4, 2002 The significance of heart-rate turbulence (HRT) in patients with chronic heart failure (CHF) was evaluated to examine whether it is sensitive to the risk of ventricular tachycardia (VT). HRT is reported to predict the prognosis after myocardial infarction (MI), but its prognostic value in patients with CHF remains unknown. HRT was measured in 50 CHF patients (left ventricular ejection fraction <50% and/or left ventricular end-diastolic diameter >55 mm, 34 cardiomyopathy, 16 post-MI) and 21 patients without obvious heart diseases (control). HRT slope and HRT onset were measured by the original definitions using digitized Holter ECG recordings. Cardiac pump function was assessed by echocardiography. The value of the HRT slope was significantly lower in CHF than in control (3.7±1.7 vs 16.4±5.3, mean ± SD, p<0.01). The value of the HRT onset in patients with CHF was significantly higher than that in control patients (-1.1±1.9 vs -3.6±1.7, mean ± SD, p<0.05). The HRT slope and onset in CHF patients with VT were nearly identical to those without VT. The HRT slope appears to be a powerful prognostic marker that shows significant differences between CHF subgroups when divided by clinical events; that is, CHF death and CHF hospitalization. However, it has limited value for predicting fatal ventricular arrhythmias. (Circ J 2002; 66: 902 -907) 
ecently, Schmidt et al reported the use of a new prognostic marker 'heart rate turbulence' (HRT) in patients with myocardial infarction. 1 It is assessed by 2 parameters (turbulence onset and slope) derived from analyzing the fluctuation of RR intervals after a single ventricular premature beat (VPB). The turbulence onset indicates an overshoot decrease in the RR interval just after a VPB pause, and the turbulence slope indicates how fast the RR interval changes after the pause. However, the underlying mechanisms of the HRT are not yet understood, and it remains unknown whether HRT is a useful marker in patients with other heart diseases. The purpose of the present study was to evaluate the prognostic significance of HRT in chronic heart failure (CHF) patients as compared with other prognostic markers such as pump function 2, 3 and heart rate variability (HRV). [4] [5] [6] In addition, it is well recognized that the incidence of sudden cardiac death (SCD) because of fatal ventricular tachycardia (VT) is considerably high in CHF patients, 7 ,8 so we also tested whether HRT is a marker for VT in CHF patients as compared with other markers including late potential (LP), 9, 10 QT dispersion (QTd) 11 and microvolt T wave alternans (TWA). [12] [13] [14] [15] 
Methods

Patient Selection
The present study was a single center study. All examinations were performed in Tohoku University Hospital from 1998 to 2000. Most cases were outpatients, but some patients were examined just before discharge. The patients were followed up by medical records and/or interview by phone. a left ventricular ejection fraction (LVEF) <50% or a left ventricular end-diastolic diameter (LVDD) >55 mm. HRT was also measured in an age-matched control population (21 patients without cardiovascular diseases) (Table 1) CHF patients were all stable for at least 3 weeks before enrollment. LVDD and LVEF were measured with Mmode and B-mode echocardiography. Echocardiography was performed at enrollment.
R
Measurement of HRT
All patients underwent noninvasive evaluation comprising a physical examination, 12-lead ECG, chest radiography, M-mode and B-mode echocardiography, and 24-h Holter ECG. The HRT slope and turbulence onset were calculated by the original method, 1 as shown in Fig 1. QRS detection and measurement of the RR interval (RRI) were automatically performed by a digitized Holter analyzer (SCM-2000, Fukuda Denshi, Tokyo, Japan). The RRI data were transferred to a personal computer, and the HRT slope and onset were calculated by our original software.
The HRT onset was defined as the difference between the mean of the first 2 sinus RRIs after a VPB, and the last 2 sinus RRIs before the VPB divided by the mean value of the last 2 sinus RR intervals before the VPB. The value of the turbulence onset is expressed as a percentage. These measurements were performed in several episodes (at least 2 episodes) containing VPB, and the values were averaged in each patient to obtain the patient's data. Positive values of HRT onset indicate sinus rhythm deceleration after VPB, and negative values indicate acceleration.
The HRT slope was defined as the maximum positive value of the slope of a regression line assessed over any sequence of five subsequent sinus-rhythm RRIs within the first 20 sinus-rhythm intervals after VPB. The value of the HRT slope was expressed in ms per RRI.
The episodes with VPB were played back on a video monitor to confirm that they were adequate for analysis. HRV was assessed by frequency and time domain analysis using the Holter recordings. For time-domain analysis, the standard deviation of normal RRIs over a 24-h period (SDNN) 16 level <0.4 V. Late potentials were considered to be present if any 2 of the following 3 criteria were present: (1) filtered QRS complex >120 ms, (2) root-mean-square voltage during the last 40 ms of the filtered QRS complex <20 V and (3) duration of the filtered QRS complex <40 ms after the voltage was decreased to less than 38 V. Cases with bundle branch block were excluded from the late potential analysis. A 12-lead ECG was recorded at 25 mm/s in all subjects. The QT interval was measured from the onset of the QRS complex to the end of the T wave, which was detected as the return of the T wave to the isoelectric line. In the presence of a U wave, the end of the T wave was defined as the intersection of the tangent to the repolarization slope with the isoelectric line. If the end of the T wave was not clearly identifiable, that particular lead was excluded from analysis. The corrected QT interval (QTc) was derived from Bazett's formula. 17 QTc dispersion was calculated as the difference between the maximum and minimum QTc intervals over all 12 leads. The exercise-induced TWA was examined using a CH2000 system with an ergometer (Cambridge Heart, Bedford, MA, USA). The initial workload was set at 10 W and increased by 10 W every 2 min. The target HR was 110 beats/min and maintained for at least 1 min. The exercise-induced TWA was considered to be positive according to the current criteria. 13, 14 (the alternans voltage exceeded 1.9 V with the alternans ratio >3.0 in at least 2 dependent leads for more than 1 min).
Data Analysis
All data are presented as mean ± SD. Statistical differences were assessed by ANOVA and the method of Bonferroni. Student's t-test was used to compare the data of 2 groups. P<0.05 was considered statistically significant. Chi square test was performed to compare some data between 2 groups. Patients with CHF were prospectively followed up. Kaplan-Meier survival curve analysis and logrank test were performed to assess the prognostic value of HRT. The start point was enrollment in the study, and the end-points were death from any cause and hospitalization from worsening CHF.
Stepwise Cox regression was used to analyze the association of the variables including age, DCM, LVEF ≤40%, LVDD >65 mm, HRT slope ≤3 ms/RRI, HRT onset <0, SDNN <70 ms and LF/HF. The end-point was CHF death or hospitalization for the deterioration of CHF.
Results
HRT in CHF Patients With Worsening Heart Failure
HRT was examined in 50 CHF patients (34 primary or secondary DCM, 16 previous MI) and 21 normal control patients without cardiovascular diseases (Fig 2) . The value of the HRT slope was significantly lower in CHF patients (3.6±1.7 vs 16.4±5.2 ms/RRI, p<0.01). The value of the HRT onset was significantly higher in CHF patients (-1.1±1.9 vs -2.5±1.7%, p<0.05). During a mean follow up period of 26±14 months, 5 patients died from worsening CHF, 1 patient died suddenly and 14 were hospitalized from worsening CHF. CHF. Beta-blockers were transiently stopped before the Holter ECG recording because they would otherwise affect HRV, 18 but amiodarone was continued. These drugs were used in nearly equal incidence between patients with and without worsening CHF. The echocardiographic LVEF in patients who died from CHF was significantly lower than that of other CHF and control patients. LVEF in patients hospitalized because of worsening CHF was not different from that in patients without worsening CHF. Table 3 summarizes the HRT and HRV in the CHF and control patients. The value of the HRT slopes in patients who died from CHF and those who were hospitalized for CHF were significantly lower than those in patients without worsening CHF. The value of the HRT onset was significantly higher in CHF patients than in control patients (Fig 2) . However, no significant difference was found among the CHF subgroups divided by prognosis. SDNN in patients who died from CHF was significantly lower than that of other CHF groups and control patients. The total power of HRV in CHF-death patients was also lower than those of other CHF and control patients. SDNN and total power in patients hospitalized by worsening CHF were not significantly different from those of CHF patients without worsening. The LF, HF, and LF/HF ratio failed to demonstrate significant differences among the CHF subgroups. Fig 3 and 4 show the correlations between HRT, LVEF, and HRV in the pooled data from CHF patients. The HRT slope was significantly correlated with the LVEF, SDNN, and LF/HF of HRV, and the HRT onset was significantly correlated with SDNN, but not with LVEF. Fig 5 shows the Kaplan-Meier survival curves, dividing CHF patients by the value of the HRT slope (≤3.0 or >3.0). The survival rate of CHF patients with a low HRT slope (≤3.0) was significantly worse in terms of both actual survival and hospitalization-free survival. In patients with a HRT slope >3.0, no patient died from worsening CHF. There were no significant differences between the 2 groups in age (57±15 vs 52±16 years, NS). LVEF was significantly lower in patients with HRT slope ≤3.0 (0.34±0.11 vs 0.42±0.09, p<0.05) and in those patients, SDNN was significantly lower (56±17 vs 77±13 ms, p<0.01).
Multivariate Cox-regression analysis revealed that HRT ≤3 and EF ≤40% were the only statistically significant predictors of CHF events (ie, death and hospitalization). The hazard ratio of the slope of HRT ≤3 was 10.9 (95% confidence interval 3.2-37.5) and the hazard ratio of EF ≤40% was 3.01 (95% CI 1.00-9.03).
HRT in CHF Patients With Sustained VT
To examine whether HRT can predict fatal ventricular arrhythmias, CHF patients were divided into 2 groups by the presence of ventricular tachycardia (>6 consecutive VPB, RR ≤400 ms) documented in the past history and/or the follow-up period. The case of sudden death was catego- rized into the VT group, which included 15 sustained VT or ventricular fibrillation (VF) and 17 non-sustained VT. The mean LVEF of the VT group was 0.39±0.12, and that of the non VT group was 0.39±0.10 (NS), as shown in Table 3 . Table 4 also summarizes HRT, LP, QTc dispersion, and TWA in CHF patients with or without VT. Both HRT slope and onset were nearly identical between these 2 groups, whereas QTc dispersion was significantly greater in patients with VT, and the positive rates of LP and TWA in patients with VT/VF were significantly higher than those in patients without VT.
Discussion
The value of the HRT slope was lower, and the HRT onset was significantly higher than those of the control patients. In particular, the HRT slope (≤3.0) appears to be a powerful prognostic marker not only for CHF death but also for CHF hospitalization from worsening CHF. However, the HRT does not appear to reflect the presence of myocardial substrates for VT.
HRT as a Predictor for Progression of CHF
The values of the HRT slope and onset in the patients with CHF were significantly different from those of the control group. The value of the HRT slope was quite low in patients who died from CHF and was significantly lower in patients hospitalized for CHF than in event-free CHF patients. Although Schmidt et al described HRT as a powerful predictor of mortality after acute MI, 1 it was not known whether it could predict the prognosis of CHF patients. The present study suggests that the HRT slope is a powerful predictor for CHF death and hospitalization. Pump function (LVEF) and HRV (SDNN) failed to show a significant difference between patients with and without hospitalization. Thus, the HRT slope appears to be a more suitable prognostic marker for CHF than either left ventricular function or HRV, as was shown in patients with acute MI. 1 The mechanisms of the decreased HRT slope in patients with CHF are not clear. Davies et al 19 and Mrowka et al 20 reported that HRT was closely correlated with the blood pressure turbulence that is determined by the baroreflex sensitivity in patients with CHF. The present data indicate that both the HRT slope and onset were significantly correlated with SDNN and that the HRT slope only was significantly correlated with LVEF (Fig 3) . Thus, not only the cardiac autonomic status but also the left ventricular function are probably involved. It is likely that the HRT slope is more susceptible to CHF events because it correlates with both the left ventricular function and the cardiac autonomic status; in other words, the HRT slope appears to be a prognostic marker that reflects left ventricular function and cardiac autonomic status. Table 5 shows the significant correlation of the HRT slope with SDNN, HF, and the LF/HF ratio of HRV. Thus, both sympathetic and parasympathetic activities may affect the HRT slope.
The value of the HRT onset in patients with CHF was significantly higher than that in control patients. Although the value of the HRT onset appears to be higher in patients with worsening CHF, the differences were not statistically significant in the present study. Also, multivariate Coxregression analysis showed that the HRT onset was not a significant predictor for cardiac events in the present study.
HRT as a Predictor for Fatal Ventricular Arrhythmia
The HRT in patients with and without VT was nearly identical in terms of both the slope and onset (Table 4) , whereas QTc dispersion was greater in CHF patients with VT, and the positive rates of the late potential and T wave alternans were also significantly greater in CHF patients with VT. Thus, HRT failed to reflect the presence of myocardial substrates for VT in the present study.
It is unknown whether HRT could predict sudden cardiac death (SCD) or VT in patients with MI and/or CHF and it remains controversial whether HRV can predict SCD and/or VT. 6, 21, 22 The present data suggest that neither HRT nor HRV can detect the presence of VT in these patients. On the other hand, QTc dispersion, late potential, and T wave alternans demonstrated significant differences between CHF patients with and without VT in the present study and in previous reports. [9] [10] [11] [12] 
Study Limitations
The present study strongly suggests that HRT is a powerful prognostic marker and should be investigated in patients with CHF. However, this was a partially prospective study with a limited number of CHF cases. In particular, most VT events were retrospectively identified. Therefore, we need to confirm the present results using a full prospective study with a larger number of CHF cases. Additionally, the etiologies of CHF were limited to dilated cardiomyopathy and MI. It remains unclear whether HRT can work in CHF caused by other etiologies, such as valvular disease and/or hypertrophic heart diseases. Although Schmidt et al adopted 2.5 ms/RRI of HRT slope as a threshold value in their original paper, 1 we used 3.0 ms/RRI in the present study because that showed the best sensitivity (84%) and specificity (87%) for the cardiac events.
In summary, the values of the HRT slope and onset for CHF patients were significantly different from those of control patients. In particular, the value of the HRT slope demonstrated significant differences among the CHF subgroups divided by prognosis, but the value of the HRT onset did not. The present data suggest that the HRT slope is a more powerful prognostic maker than the HRT onset. The HRT slope (≤3.0) can predict not only CHF death but also worsening CHF (ie, hospitalization). It correlated with both left ventricular function and cardiac autonomic status (HRV). However, HRT was nearly identical between CHF patients with and without VT.
In conclusion, HRT, especially the HRT slope, is a potential prognostic marker for CHF patients and needs to be further investigated. HRT has limited value for predicting fatal VT. 
